Method for repairing neurodegeneration

Abstract

The present invention provides for treating neurodegeneration caused by nerve compression syndrome or entrapment neuropathy comprising administering human acidic fibroblast growth factor (aFGF), fibrinogen, aprotinin and divalent calcium ions to a subject in need thereof.

1 . A method for treating neurodegeneration caused by nerve compression syndrome or entrapment neuropathy comprising administering a human acidic fibroblast growth factor (aFGF) as the sole therapeutic agent to a subject in need thereof, wherein the human aFGF is mixed with fibrinogen, aprotinin and divalent calcium ions to form a fibrin glue mixture and then administered intrathecally or intramuscularly. 
     
     
         2 . The method according to  claim 1 , wherein the nerve compression syndrome or entrapment neuropathy is caused by a chronic compression, acute compression, or a mechanical injury. 
     
     
         3 . The method according to  claim 1 , wherein the nerve compression or entrapment neuropathy is caused by herniated intervertebral disc, cervical nerve compression syndrome, thoracic outlet syndrome, or carpal tunnel syndrome. 
     
     
         4 . The method according to  claim 1 , wherein the human aFGF comprises a deletion of the first 20 amino acids from N-terminus of the native human aFGF followed by an addition of Alanine at the N-terminus of the shortened native aFGF. 
     
     
         5 . The method according to  claim 1 , wherein the divalent calcium ions are provided by the addition of calcium chloride or calcium carbonate. 
     
     
         6 . The method according to  claim 1 , wherein the fibrin glue mixture comprises 0.01-100 mg/ml of human aFGF, 10-1000 mg/ml of fibrinogen, 10-500 KIU/ml of aprotinin and 0.1-10 mM of calcium chloride. 
     
     
         7 . The method according to  claim 1 , wherein the fibrin glue mixture comprises 0.04 mg/ml human aFGF, 10 mg/ml of fibrinogen, 200 KIU/ml of aprotinin and 0.45 mM of calcium chloride. 
     
     
         8 . The method according to  claim 1 , wherein the human aFGF is administered intrathecally. 
     
     
         9 . The method according to  claim 1 , wherein the human aFGF is administered intramuscularly. 
     
     
         10 . The method according to  claim 8 , wherein the human aFGF is administered through the foramen magnum.